RGEN REPLIGEN CORP
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 730272 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY-779.2%
TTM EPS YoY-1,150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.8%
Operating margin2.3%
Net margin-1.5%
FCF margin13.2%
EBITDA margin11.9%
Returns
ROE-0.6%
ROA-0.4%
ROIC (approx.)0.5%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets28.5%
Debt / equity0.27x
Current ratio9.88x
Interest coverage0.81x
Cash quality & payout
Operating cash flow / net income-11.00x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $209.31M | $204.13M | $194.25M | $197.91M | $188.81M | $182.37M | $169.17M | $167.55M |
| Cost of revenue | $98.33M | $94.09M | $85.97M | $94.08M | $88.29M | $89.37M | $77.80M | $128.71M |
| Gross profit | $110.99M | $110.04M | $108.28M | $103.83M | $100.52M | $93.00M | $91.37M | $38.84M |
| R&D expense | $14.44M | $14.42M | $14.46M | $13.12M | $14.18M | $13.97M | $12.11M | $11.68M |
| SG&A expense | $83.59M | $76.62M | $76.54M | $74.36M | $73.66M | $70.91M | $70.71M | $60.47M |
| Operating income | -$29.55M | $13.98M | $15.94M | $17.87M | $16.82M | $13.90M | $6.58M | -$36.50M |
| Interest expense | $5.71M | $5.66M | $5.58M | $5.50M | $5.41M | $5.35M | $5.25M | $5.46M |
| Pretax income | -$26.81M | $14.15M | $1.77M | $19.11M | $17.11M | $18.21M | $7.94M | -$38.61M |
| Income tax | $11.62M | $9.14M | -$6.56M | $5.83M | $2.20M | $3.35M | $2.11M | -$4.74M |
| Net income | -$38.43M | $5.01M | $8.33M | $13.29M | $14.91M | $14.87M | $5.83M | -$33.87M |
| EBITDA | -$10.42M | $33.04M | $35.70M | $37.82M | $36.83M | $33.98M | $25.28M | -$18.13M |
| EPS (basic) | -0.68 | 0.09 | 0.15 | — | 0.27 | 0.26 | 0.10 | — |
| EPS (diluted) | -0.68 | 0.09 | 0.15 | — | 0.26 | 0.26 | 0.10 | — |
| Weighted avg. shares (diluted) | 56.56M | 56.64M | 56.67M | — | 56.53M | 56.51M | 56.56M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $726.96M | $606.78M | $582.65M | $566.02M | $748.75M | $708.86M | $697.23M | $757.36M |
| Short-term investments | $136.02M | $203.67M | $201.88M | $201.61M | — | — | — | $0 |
| Receivables | $151.24M | $157.71M | $151.55M | $158.59M | $148.97M | $156.95M | $147.41M | $134.12M |
| Inventory | $182.21M | $186.60M | $179.26M | $170.46M | $160.32M | $155.86M | $153.11M | $142.96M |
| Current assets | $1.24B | $1.20B | $1.16B | $1.14B | $1.10B | $1.06B | $1.03B | $1.07B |
| PP&E, net | $163.56M | $167.51M | $173.46M | $186.61M | $188.93M | $193.49M | $195.52M | $197.74M |
| Goodwill | $1.10B | $1.10B | $1.11B | $1.11B | $1.11B | $1.11B | $1.08B | $1.03B |
| Intangibles | $305.29M | $357.62M | $368.19M | $386.15M | $395.44M | $406.21M | $409.23M | $397.90M |
| Total assets | $2.93B | $2.95B | $2.93B | $2.95B | $2.92B | $2.90B | $2.85B | $2.83B |
| Current liabilities | $125.69M | $132.66M | $126.21M | $135.83M | $131.14M | $123.01M | $152.00M | $126.79M |
| Long-term debt | $555.60M | $551.05M | $546.59M | $542.21M | $537.93M | — | — | $525.57M |
| Total debt | $555.60M | $551.05M | $546.59M | $542.21M | $537.93M | — | — | $525.57M |
| Total liabilities | $834.67M | $838.15M | $825.31M | $843.57M | $840.62M | $839.89M | $866.66M | $856.95M |
| Shareholders' equity | $2.09B | $2.11B | $2.11B | $2.11B | $2.08B | $2.06B | $1.99B | $1.97B |
| Net debt | -$171.36M | -$55.74M | -$36.06M | -$23.81M | -$210.82M | — | — | -$231.79M |
| Shares outstanding | 56.69M | 56.43M | 56.40M | 56.33M | 56.28M | 56.25M | 56.18M | 56.09M |
| Cash flow statement | ||||||||
| Operating cash flow | $43.10M | $32.77M | $28.30M | $25.70M | $48.10M | $28.61M | $15.01M | $39.18M |
| Capital expenditure | $4.95M | $5.33M | $4.71M | $8.15M | $4.70M | $7.10M | $3.56M | $5.54M |
| Free cash flow | $38.15M | $27.43M | $23.59M | $17.55M | $43.40M | $21.51M | $11.44M | $33.64M |
| Investing cash flow | $63.99M | -$2.09M | -$3.99M | -$208.74M | -$7.78M | -$7.84M | -$74.11M | -$64.76M |
| Financing cash flow | $14.60M | -$6.20M | -$5.54M | $195,000 | -$239,000 | -$10.13M | -$5.03M | $1.45M |
| Depreciation & amortization | $19.12M | $19.06M | $19.76M | $19.95M | $20.01M | $20.08M | $18.70M | $18.37M |
| Stock-based compensation | $9.36M | $8.01M | $8.32M | $7.98M | $8.97M | $8.38M | $7.27M | $6.36M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.